Semax Peptide Reverses Long-Term Stress Effects from Early Life Trauma in Rats

Early life stress, such as neonatal isolation, can lead to profound and long-lasting behavioral and neurobiological deficits, mirroring aspects of post-traumatic stress disorder (PTSD) and depression in humans. These deficits often include anxiety-like behaviors, cognitive impairments, and altered stress responses. Current treatments often have limited efficacy or significant side effects, highlighting a need for novel therapeutic strategies. This study specifically investigated if Semax could mitigate these persistent negative effects of early-life stress in an animal model.

Treatment with Semax significantly improved several stress-induced behavioral deficits. In the elevated plus maze, rats receiving 0.5 mg/kg Semax spent 45% more time in the open arms compared to controls (p<0.01), indicating reduced anxiety-like behavior. Cognitive performance, assessed via a novel object recognition test, showed a 2.3-fold increase in discrimination index in the high-dose Semax group (p<0.05). The most significant finding was a 60% reduction in stress-induced immobility time in the forced swim test in rats treated with 0.5 mg/kg Semax compared to untreated isolated controls (p<0.001), suggesting a potent antidepressant-like effect. Furthermore, the lower dose of 0.1 mg/kg Semax also showed beneficial effects, with a 25% improvement in exploratory activity in the open field test (p<0.05). These findings demonstrate Semax's ability to reverse established long-term consequences of early life stress.